AAAAAA

   
Results: 1-25 | 26-39
Results: 1-25/39
WHERE DO WE STAND ON NEUROPROTECTION - WHERE DO WE GO FROM HERE
Authors: SHOULSON I
Citation: I. Shoulson, WHERE DO WE STAND ON NEUROPROTECTION - WHERE DO WE GO FROM HERE, Movement disorders, 13, 1998, pp. 46-48
DATATOP - A DECADE OF NEUROPROTECTIVE INQUIRY
Authors: SHOULSON I
Citation: I. Shoulson, DATATOP - A DECADE OF NEUROPROTECTIVE INQUIRY, Annals of neurology, 44(3), 1998, pp. 160-166
MORTALITY IN DATATOP - A MULTICENTER TRIAL IN EARLY PARKINSONS-DISEASE
Authors: SHOULSON I OAKES D FAHN S LANG A LANGSTON JW LEWITT P OLANOW CW PENNEY JB TANNER C KIEBURTZ K KOLLER W RODNITZKY R FINK JS GROWDON JH PAULSON G KURLAN R FRIEDMAN JH GANCHER S NUTT J RAJPUT AH BENNETT JB WOOTEN GF GOETZ C SHANNON K SUCHOWERSKY O BRIN MF BRESSMAN SB WEINER WJ SANCHEZRAMOS J JANKOVIC J TETRUD J GRIMES JD PFEIFFER R SHULTS C THAL L GAUTHIER S GOLBE LI PERLMUTTER JS MOSES H REICH SG HURTIG HI STERN M BARTER R VETEREOVERFIELD B GAUGER L MALAPIRA T DOBSON J ATAMIAN S TENNIS M COHEN JB DESCLOS G HOFFMAN E GRAEFE K BURKE C MARCUS A DENIO L HUBER S WOIKE T ZOOG K MENDELL R DUDTE K BEHR J GARDINER IF LANNON M CARTER J NORTHRUP S KANIGAN B TURK M LANDOW E SCHLICK P MISTURA K CARROLL VS THELEN JA DEMONG C WINFIELD L MOSKOWITZ C INGENITO A SHELDON C CORNELIUS L HEIBERG D DUNNE C BRADY J KIERANS C BELLESCANTLEBURY L DUFF J WEBER H SAVOINI D LEWIS P KUTNER SJ GRAY P GLAESKE C HOFMAN R PAY M SALMON D MCFAUL F AMYOT D BERGEN M MCGEEMINNICH L ODONNELL P FERRISE S SHALLOW K
Citation: I. Shoulson et al., MORTALITY IN DATATOP - A MULTICENTER TRIAL IN EARLY PARKINSONS-DISEASE, Annals of neurology, 43(3), 1998, pp. 318-325
EXPERIMENTAL THERAPEUTICS OF NEURODEGENERATIVE DISORDERS - UNMET NEEDS
Authors: SHOULSON I
Citation: I. Shoulson, EXPERIMENTAL THERAPEUTICS OF NEURODEGENERATIVE DISORDERS - UNMET NEEDS, Science, 282(5391), 1998, pp. 1072-1074
SAFETY AND TOLERABILITY OF THE FREE-RADICAL SCAVENGER OPC-14117 IN HUNTINGTONS-DISEASE
Authors: SHOULSON I PENNEY J KIEBURTZ K OAKES D CHASE T CHOI D MARDER K MOSKOWITZ C ZUBIN N VENTURA P FEIGIN A HICKEY C COMO P RICHARD IH GOLDSTEIN J HERSCH S BISSEYBLACK C JONES R SWENSON M BELL J PAULSEN JS SWENSON A TAWFIKREEDY Z ORME C PLUMB S RUDOLPH A CLAUDE K MCMULLEN N DAY D MARSHALL FJ BOURGEOIS K WATTS A TARIOT PN JACKSON WJ HALL WJ MADDREY W BIZIERE K JAFFE M
Citation: I. Shoulson et al., SAFETY AND TOLERABILITY OF THE FREE-RADICAL SCAVENGER OPC-14117 IN HUNTINGTONS-DISEASE, Neurology, 50(5), 1998, pp. 1366-1373
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF DEPRENYL AND THIOCTIC ACID IN HUMAN IMMUNODEFICIENCY VIRUS-ASSOCIATED COGNITIVE IMPAIRMENT
Authors: SACKTOR N KIEBURTZ K SCHIFITTO G MCDERMOTT M BOURGEOIS K PALUMBO D ORME C ZIMMERMAN C GELBARD H HICKEY C CASACELI C GUTHRIE B RUMFOLA L PLUMB S RUDOLPH A KAMP C EPSTEIN L MARDER K ALBERT S DOONEIEF G STERN Y TODAK G FRIEDMANCLOUSE R POLANCO C WINSTON T MAYEUX R SACKTOR N SELNES O HASENAUER D ESPOSITO D NANCESPROSON L MCARTHUR J OSULLIVAN J SHOULSON I OAKES D REICHMAN R
Citation: N. Sacktor et al., A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF DEPRENYL AND THIOCTIC ACID IN HUMAN IMMUNODEFICIENCY VIRUS-ASSOCIATED COGNITIVE IMPAIRMENT, Neurology, 50(3), 1998, pp. 645-651
A CONTROLLED TRIAL OF FLUOXETINE IN NONDEPRESSED PATIENTS WITH HUNTINGTONS-DISEASE
Authors: COMO PG RUBIN AJ OBRIEN CF LAWLER K HICKEY C RUBIN AE HENDERSON R MCDERMOTT MP MCDERMOTT M STEINBERG K SHOULSON I
Citation: Pg. Como et al., A CONTROLLED TRIAL OF FLUOXETINE IN NONDEPRESSED PATIENTS WITH HUNTINGTONS-DISEASE, Movement disorders, 12(3), 1997, pp. 397-401
ENTACAPONE IMPROVES MOTOR FLUCTUATIONS IN LEVODOPA-TREATED PARKINSONS-DISEASE PATIENTS
Authors: KIEBURTZ K SHOULSON I FAHN S MCDERMOTT M KOLLER W LEWITT P NUTT J KURTH M BREWER M LEW M WELSH M WATERS C BENNETT J ROSTRUFFNER E FEIGIN A GARDINER I KURLAN R HAMMERSTAD J STONE C JANKOVIC J BEACH J TETRUD J KELKER K STANDAERT DG GROWDON JH TENNIS M GRAEFE K MARK MH KELLY SJ PAHWA R MCGUIRE D HUBBLE J FACTOR SA BROWN DL TUITE P SIME E LANG DL GREENE P WINFIELD H PAULSON G ZOOG K WEEKS C SHULTS C FONTAINE D JUNCOS JL WOOD C SHANNON K JAGLIN JA TORNABENE J LANNON MC DAVIES R FRIEDMAN J TARIOT PN HALL WJ HERNDON R PFEIFFER RF PLUMB S CASACELI C RANDOLPH H BEHMAN H CONNORTON J DAY D RUDOLPH A PELUSIO R GUTHRIE B CLAUDE K ORME C BAKER D NOBEL R IRVINE C WATTS A GORDIN A HEIKKINEN H RITA H
Citation: K. Kieburtz et al., ENTACAPONE IMPROVES MOTOR FLUCTUATIONS IN LEVODOPA-TREATED PARKINSONS-DISEASE PATIENTS, Annals of neurology, 42(5), 1997, pp. 747-755
SAFETY AND EFFICACY OF PRAMIPEXOLE IN EARLY PARKINSON DISEASE - A RANDOMIZED DOSE-RANGING STUDY
Authors: KIEBURTZ K SHOULSON I MCDERMOTT M FAHN S LANG A OLANOW W PENNEY J WOOTEN GF KURLAN R GARDINER I PETZINGER G BRIN M DILLON S SHANNON K JAGLIN JA TROSCH R MISTURA K HARRISON M ROSTRUFFNER E TANNER C SINGER C WEINER W SHELDON C GRIMES JD GRAY P HURTIG H HAUSER R GAUGER L RAJPUT A RUDNITZKY R DOBSON J PANISSET M GAUTHIER S AMYOT D PERLMUTTER J HUBBLE J BARTER R SUCHOWERSKY O LEW M WELSH M MAREK K FUSSELL B SETHI K LIGON K RAO J RUDOLPH A CASACELI C DAY D JOHNSTON K BAKER D CHERNE C WATTS A TARIOT PN GRIGGS RC HALL WJ PETERS G CORRIGAN M BRYAN W SCHWARTZ J NEIDERT G LAI PY
Citation: K. Kieburtz et al., SAFETY AND EFFICACY OF PRAMIPEXOLE IN EARLY PARKINSON DISEASE - A RANDOMIZED DOSE-RANGING STUDY, JAMA, the journal of the American Medical Association, 278(2), 1997, pp. 125-130
IMMEDIATE AND SUSTAINED-RELEASE OF METHYLPHENIDATE - TIME-COURSE EFFECTS ON ADHD CHILDREN
Authors: WIGAL S SWANSON J GUPTA S GUINTA D CROWLEY K FLYNN D AGLER D LERNER M WILLIAMS L CANTWELL D BAREN M ELLIOTT G FONTANA D SHOULSON I
Citation: S. Wigal et al., IMMEDIATE AND SUSTAINED-RELEASE OF METHYLPHENIDATE - TIME-COURSE EFFECTS ON ADHD CHILDREN, Psychopharmacology bulletin, 33(3), 1997, pp. 604-604
SAFETY AND TOLERABILITY OF THE ANTIOXIDANT OPC-14117 IN HIV-ASSOCIATED COGNITIVE IMPAIRMENT
Authors: KIEBURTZ K SCHIFITTO G MCDERMOTT M HEO M IRVINE C PALUMBO D ORME C ZIMMERMAN C GELBARD H HICKEY C CASACELI C GUTHRIE B RUMFOLA L EPSTEIN L MARDER K RAMACHANDRAN G ALBERT S DOONEIEF G STERN Y TODAK G FRIEDMANCLOUSE R POLANCO C WINSTON T MAYEUX R DALPAN G SELNES O SACKTOR N HASENAUER D ESPOSITO D NANCESPROSON L MCARTHUR JC SHOULSON I OAKES D REICHMAN R OSULLIVAN J
Citation: K. Kieburtz et al., SAFETY AND TOLERABILITY OF THE ANTIOXIDANT OPC-14117 IN HIV-ASSOCIATED COGNITIVE IMPAIRMENT, Neurology, 49(1), 1997, pp. 142-146
SEROTONIN SYNDROME AND THE COMBINED USE OF DEPRENYL AND AN ANTIDEPRESSANT IN PARKINSONS-DISEASE
Authors: RICHARD IH KURLAN R TANNER C FACTOR S HUBBLE J SUCHOWERSKY O WATERS C GOETZ C JUNCOS JL STERN M HARRISON MB SETHI KD STANDAERT D TROSCH R REICH S KIEBURTZ K FEIGIN A MARSHALL FJ GAUTHIER S PANISSET M LEW ME FRIEDMAN JH PAULSON G RODNITZKY RL HAUSER R KURTH M HURTIG H THAL L ELMER LW PERLMUTTER JS GOLBE LI COMELLA C LANG A MARK MH SINGER C SHOULSON I WEINER WJ PFEIFFER R MAREK KL NUTT J WOOTEN GF JANKOVIC J LEWITT P HOEHN M BENNETT J PARSA M KOLLER W
Citation: Ih. Richard et al., SEROTONIN SYNDROME AND THE COMBINED USE OF DEPRENYL AND AN ANTIDEPRESSANT IN PARKINSONS-DISEASE, Neurology, 48(4), 1997, pp. 1070-1077
A CONTROLLED TRIAL OF REMACEMIDE HYDROCHLORIDE IN HUNTINGTONS-DISEASE
Authors: KIEBURTZ K FEIGIN A MCDERMOTT M COMO P ABWENDER D ZIMMERMAN C HICKEY C ORME C CLAUDE K SOTACK J GREENAMYRE JT DUNN C SHOULSON I
Citation: K. Kieburtz et al., A CONTROLLED TRIAL OF REMACEMIDE HYDROCHLORIDE IN HUNTINGTONS-DISEASE, Movement disorders, 11(3), 1996, pp. 273-277
ASSESSMENT OF COENZYME-Q10 TOLERABILITY IN HUNTINGTONS-DISEASE
Authors: FEIGIN A KIEBURTZ K COMO P HICKEY C CLAUDE K ABWENDER D ZIMMERMAN C STEINBERG K SHOULSON I
Citation: A. Feigin et al., ASSESSMENT OF COENZYME-Q10 TOLERABILITY IN HUNTINGTONS-DISEASE, Movement disorders, 11(3), 1996, pp. 321-323
UNIFIED HUNTINGTONS-DISEASE RATING-SCALE - RELIABILITY AND CONSISTENCY
Authors: KIEBURTZ K PENNEY JB COMO P RANEN N SHOULSON I FEIGIN A ABWENDER D GREENAMYRE JT HIGGINS D MARSHALL FJ GOLDSTEIN J STEINBERG K SHIH C RICHARD I HICKEY C ZIMMERMAN C ORME C CLAUDE K OAKES D SAX DS KIM A HERSCH S JONES R AUCHUS A OLSEN D BISSEYBLACK C RUBIN A SCHWARTZ R DUBINSKY R MALLONEE W GRAY C GODFREY N SUTER G SHANNON KM STEBBINS GT JAGLIN JA MARDER K TAYLOR S LOUIS E MOSKOWITZ C THORNE D ZUBIN N WEXLER N SWENSON MR PAULSEN J SWERDLOW N ALBIN R WERNETTE C WALKER F HUNT V ROOS RAC YOUNG AB KOROSHETZ W BIRD E MEYERS R CUDKOWICZ M GUTTMAN M STCYR J BURKHOLDER J LUNDIN A ASHIZAWA T JANKOVIC J SIEMERS E QUAID K MARTIN W SANCHEZRAMOS J FACCA A REY G SUCHOWERSKY O ROHS G KLINEK ML ROSS C BYLSMA FW SHERR M HAYDEN M RAYMOND L CLARK C KREMER B
Citation: K. Kieburtz et al., UNIFIED HUNTINGTONS-DISEASE RATING-SCALE - RELIABILITY AND CONSISTENCY, Movement disorders, 11(2), 1996, pp. 136-142
CLINICAL RESEARCH IN NEUROLOGY - FROM OBSERVATION TO EXPERIMENTATION
Authors: MARSHALL FJ KIEBURTZ K MCDERMOTT M KURLAN R SHOULSON I
Citation: Fj. Marshall et al., CLINICAL RESEARCH IN NEUROLOGY - FROM OBSERVATION TO EXPERIMENTATION, Neurologic clinics, 14(2), 1996, pp. 451
STUDY DESIGN-PROBLEMS OF DATATOP STUDY ANALYSIS - REPLY
Authors: PENNEY JB SHOULSON I KIEBURTZ K OAKES D
Citation: Jb. Penney et al., STUDY DESIGN-PROBLEMS OF DATATOP STUDY ANALYSIS - REPLY, Annals of neurology, 40(6), 1996, pp. 947-948
EFFECT OF LAZABEMIDE ON THE PROGRESSION OF DISABILITY IN EARLY PARKINSONS-DISEASE
Authors: KIEBURTZ K MCDERMOTT M SHOULSON I FAHN S BRIN M GOETZ C LANG A OLANOW CW LEWITT P MISTURA K WATERS C WELSH M RODNITZKY R DOBSON J ARGATOFF P TANNER C LEWIS P WATTS R BRYAN B COMELLA C JAGLIN JA SHULTS C FONTAINE D BRESSMAN SB MOSKOWITZ C HURTIG HI SHALLOW K HUBBLE J BARTER R BENNETT JP ROSTRUFFNER E PERLMUTTER JS MCGEEMINNICH L HAUSER R GAUGER L RAJPUT AH SUTTON A TRINIDAD K GARDINER IF SINGER C SHELDON C FINK JS TENNIS M BAKER D BOURGEOIS K CASACELI C CLAUDE K HICKEY G NOBEL R OAKES D ORME C PELUSIO RM PLUMB S RUDOLPH A RANDOLPH P SOTACK J WATTS A TARIOT PN GOLBE LI MILLER P HALL WJ HERNDON R DORFLINGER E MYL D MODI M OARSLEY L YOO K ELIAHOU E SHIMOUN G COLLETTA S SIEGEL J PEDDER S DUPUIS D
Citation: K. Kieburtz et al., EFFECT OF LAZABEMIDE ON THE PROGRESSION OF DISABILITY IN EARLY PARKINSONS-DISEASE, Annals of neurology, 40(1), 1996, pp. 99-107
IMPACT OF DEPRENYL AND TOCOPHEROL TREATMENT ON PARKINSONS-DISEASE IN DATATOP SUBJECTS NOT REQUIRING LEVODOPA
Authors: SHOULSON I FAHN S OAKES D LANG A LANGSTON JW LEWITT P OLANOW CW PENNEY JB TANNER C KIEBURTZ K KOLLER W RODNITZKY R FINK JS GROWDON JH PAULSON G KURLAN R FRIEDMAN JH GANCHER S NUTT J RAJPUT AH BENNETT JB WOOTEN GF GOETZ C SHANNON K SUCHOWERSKY O BRIN MF BRESSMAN SB WEINER WJ SANCHEZRAMOS J JANKOVIC J HOEHN M TETRUD J GRIMES JD PFEIFFER R SHULTS C THAL L GAUTHIER S GOLBE LI PERLMUTTER JS MOSES H REICH SG HURTIG HI STERN M BARTER R VETEREOVERFIELD B GAUGER L MALAPIRA T DOBSON J ATAMIAN S TENNIS M COHEN JB DESCLOS G HOFFMAN E DENIO L HUBER S WOIKE T ZOOG K MENDELL R DUDTE K BEHR J GARDINER IF LANNON M CARTER J NORTHRUP S KANIGAN B TURK M LANDOW E SCHLICK P MISTURA K CARROLL VS THELEN JA DEMONG C WINFIELD L MOSKOWITZ C INGENITO A SHELDON C CORNELIUS L HEIBERG D DUNNE C BRADY J KIERANS C BELLESCANTLEBURY L DUFF J WEBER H SAVOINI D LEWIS P KUTNER SJ GRAY P GLAESKE C HOFMAN R PAY MM SALMON D MCFAUL F AMYOT D BERGEN M MCGEEMINNICH L ODONNELL P FERRISE S SHALLOW K BAKER D CASACELI C EBERLY S MCDERMOTT M NOBEL R ORME C PELUSIO RM PLUMB S RUDOLPH A RANDOLPH H SOTACK J WATTS A
Citation: I. Shoulson et al., IMPACT OF DEPRENYL AND TOCOPHEROL TREATMENT ON PARKINSONS-DISEASE IN DATATOP SUBJECTS NOT REQUIRING LEVODOPA, Annals of neurology, 39(1), 1996, pp. 29-36
IMPACT OF DEPRENYL AND TOCOPHEROL TREATMENT ON PARKINSONS-DISEASE IN DATATOP PATIENTS REQUIRING LEVODOPA
Authors: PENNEY JB OAKES D SHOULSON I FAHN S LANG A LANGSTON JW LEWITT P OLANOW CW TANNER C KIEBURTZ K
Citation: Jb. Penney et al., IMPACT OF DEPRENYL AND TOCOPHEROL TREATMENT ON PARKINSONS-DISEASE IN DATATOP PATIENTS REQUIRING LEVODOPA, Annals of neurology, 39(1), 1996, pp. 37-45
COEXISTENCE OF HUNTINGTONS-DISEASE AND FAMILIAL AMYOTROPHIC-LATERAL-SCLEROSIS - CASE PRESENTATION
Authors: RUBIO A STEINBERG K FIGLEWICZ DA MACDONALD ME GREENAMYRE T HAMILL R SHOULSON I POWERS JM
Citation: A. Rubio et al., COEXISTENCE OF HUNTINGTONS-DISEASE AND FAMILIAL AMYOTROPHIC-LATERAL-SCLEROSIS - CASE PRESENTATION, Acta Neuropathologica, 92(4), 1996, pp. 421-427
FUNCTIONAL DECLINE IN HUNTINGTONS-DISEASE
Authors: FEIGIN A KIEBURTZ K BORDWELL K COMO P STEINBERG K SOTACK J ZIMMERMAN C HICKEY C ORME C SHOULSON I
Citation: A. Feigin et al., FUNCTIONAL DECLINE IN HUNTINGTONS-DISEASE, Movement disorders, 10(2), 1995, pp. 211-214
EVIDENCE OF THE GLUTAMATE ANTAGONIST REMACEMIDE HYDROCHLORIDE IN HUNTINGTONS-DISEASE
Authors: KIEBURTZ K MCDERMOTT M MARSHALL FJ FEIGIN A COMO P ABWENDER D ZIMMERMAN C HICKEY C ORME C BORDWELL K SOTACK J GREENAMYRE JT DUNN C SHOULSON I
Citation: K. Kieburtz et al., EVIDENCE OF THE GLUTAMATE ANTAGONIST REMACEMIDE HYDROCHLORIDE IN HUNTINGTONS-DISEASE, Neurology, 45(4), 1995, pp. 254-254
A PROSPECTIVE EVALUATION OF COGNITIVE DECLINE IN EARLY HUNTINGTONS-DISEASE - FUNCTIONAL AND RADIOGRAPHIC CORRELATES
Authors: BAMFORD KA CAINE ED KIDO DK COX C SHOULSON I
Citation: Ka. Bamford et al., A PROSPECTIVE EVALUATION OF COGNITIVE DECLINE IN EARLY HUNTINGTONS-DISEASE - FUNCTIONAL AND RADIOGRAPHIC CORRELATES, Neurology, 45(10), 1995, pp. 1867-1873
AMYOTROPHY AND HUNTINGTONS-DISEASE (HD)
Authors: RUBIO A STEINBERG K FIGLEWICZ D GREENAMYRE T SHOULSON I HAMILL R POWERS J
Citation: A. Rubio et al., AMYOTROPHY AND HUNTINGTONS-DISEASE (HD), Journal of neuropathology and experimental neurology, 54(3), 1995, pp. 443-443
Risultati: 1-25 | 26-39